It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.

Enter Novartis. Impressed by the clinical data generated with inclisiran, Novartis bought The Medicines Company for $9.7 billion. Although it had some difficulties in its development program, Novartis has finally received FDA approval for inclisiran which Novartis will sell under the brand name Leqvio. Novartis CEO Vas Narasimhan believes that Leqvio “creates new possibilities for how healthcare systems can impact cardiovascular disease, a defining public health challenge of our time.”